VEEV · Veeva Systems

The thesis

Veeva Systems has a modestly better-than-even chance of beating the S&P 500 over the next three months. Management said on 5 November 2026 that the fiscal third quarter would meet or exceed guidance on every metric, and at least ten analyst firms raised their targets between 6 November 2026 and 11 November 2026. The 3 December 2026 report settles it: revenue against the $932–935 million guidance and the updated fiscal 2027 outlook.

The rating is Medium because the business evidence points one way and the shares have not yet followed it. The shares closed at $310.10 on 5 November 2026, before the Investor Day results were known, and between $303.73 and $306.40 in the four sessions since, ending at $304.77 on 11 November 2026 per adjusted daily closes. Wells Fargo's move to a $400 target on 11 November 2026, reported by Benzinga, is the highest of the round.

The price already reflects a clean quarter. Management pre-announced it on 5 November 2026, and the shares are up 20.6% over three months to 11 November 2026. The case therefore depends on the updated annual outlook rising above the $3,682–3,687 million range set on 26 August 2026, not on the quarter alone.

Bullish and bearish views on Veeva Systems Inc.

The bull case on Veeva Systems Inc. (VEEV), in brief: management backed third-quarter guidance. The bear case: several firms still see limited room.

Bull case

• Management backed third-quarter guidance. Veeva said on 5 November 2026 that it expects to meet or exceed its prior guidance on all metrics for the quarter ended 31 October 2026, MarketBeat reported. That guidance, set in the company's 26 August 2026 8-K, is revenue of $932–935 million and adjusted (non-GAAP) earnings per share of $2.33–2.34.
• The round of target increases kept going. Wells Fargo raised its target to $400 on 11 November 2026, and BTIG moved to $360 from $340 and Truist to $360 on 9 November 2026, Benzinga reported. Earlier, on 6 November 2026, Jefferies went to $375 from $295 and RBC Capital to $365 from $325, per Stock Observer and The Fly.
• The 2030 goal excludes newer products. MarketBeat reported on 5 November 2026 that the $6 billion revenue run-rate goal for 2030 rests on existing products. It leaves out the newer artificial intelligence (AI) and Aspen businesses, and the 35% non-GAAP operating margin target stands alongside it.
• Vault CRM commitments keep rising. Vault customer relationship management (CRM) had more than 200 live customers and selections from 14 of the top 20 biopharma companies on 5 November 2026, MarketBeat reported. Company news added UCB as a committed customer on 4 November 2026.
• Subscription growth anchors the recovery. Veeva reported on 26 August 2026 that fiscal second-quarter subscription revenue rose 16% year over year to $766.8 million. Total revenue rose 18% to $928.0 million, and annual revenue guidance rose to $3,682–3,687 million.
• The market estimate grew. Veeva put its total addressable market at $30 billion on 5 November 2026, up from $20 billion a year earlier, MarketBeat reported.

Bear case

• Several firms still see limited room. Canaccord Genuity kept a Hold rating with a $315 target on 9 November 2026, and UBS (Neutral) and Evercore ISI (In-Line) both set $325 on 6 November 2026, Benzinga reported. MarketBeat's consensus target was $309.08 on 6 November 2026, with 19 buy, 8 hold and 1 sell ratings, Stock Observer reported.
• Insiders sold into the rally. SEC Form 4 filings show Executive Vice President Daniel Rizzo sold 4,841 shares at an average $276.51 on 2 October 2026. General Counsel Jonathan Faddis sold 5,198 shares at an average $299.72 on 14 October 2026 under a Rule 10b5-1 trading plan.
• Most large customers have not yet gone live. Only five of the top 20 biopharma companies were live on Vault CRM on 5 November 2026, against 14 that had selected it, MarketBeat reported. The full migration is expected by the end of 2029, and Salesforce competes for the same accounts throughout.
• A senior executive left. Tom Schwenger, Veeva's President and Chief Customer Officer, became chief executive of Omnicom Health's marketing business, Omnicom announced on 2 November 2026. His departure falls in the middle of the CRM migration.
• Reported margins are lower than adjusted ones. GAAP operating margin was 29.6% in fiscal Q2 2027 against 44.8% non-GAAP, per the 26 August 2026 release. The 35% margin goal for 2030 is a non-GAAP figure.

Price setup

The shares closed at $304.77 on 11 November 2026. That is 6.5% below the 52-week intraday high of $325.99 set on 22 October 2026, and far above the 52-week closing low of $151.43 on 10 April 2026. The 3-month change to 11 November 2026 is 20.6%, from a $252.64 close on 13 August 2026.

On adjusted daily closes as of 11 November 2026, the 50-day moving average is $290.65 and the 200-day moving average is $212.65. The shares sit above both. The level the case turns on is the 1 October 2026 close, where the October run to new highs began and where SEC Form 4 filings show several officers' shares were withheld for tax; it lies below the 50-day average.

Since the Investor Day, the shares have traded in a narrow band: $303.73 to $306.40 on closes from 6 November to 11 November 2026. A move out of that band before the 3 December 2026 report would show which way the market leans on the updated outlook.

Catalysts ahead

• 3 December 2026: Fiscal Q3 2027 results and updated fiscal 2027 guidance, the date Veeva gave at its 5 November 2026 Investor Day. Replaces the meet-or-exceed statement with actual revenue against the $932–935 million guidance, shows whether subscription growth holds at the 16% pace, and shows whether the $3,682–3,687 million annual outlook rises.
• ~December 2026 (planned): Study Builder Agent early-adopter availability. First customer use of the AI clinical product announced on 24 September 2026, an early read on whether Veeva's AI products reach paying users.

What would change the view

A daily close below $281.93, the 1 October 2026 close that began the October run to new 52-week highs. Fiscal third-quarter revenue under the $932 million guidance floor, or a cut to the $3,682–3,687 million annual outlook, would also break the case.

The risks this note tracks, each with what would confirm it:

• Salesforce competition turns into displacement of Veeva CRM contracts during the migration that runs to the end of 2029. Confirmed by: a named biopharma customer disclosing replacement of Veeva CRM with Salesforce Life Sciences Cloud.
• Subscription growth slows after the fiscal second-quarter recovery. Confirmed by: the 3 December 2026 release reporting subscription revenue growth below the 16% disclosed on 26 August 2026.
• The updated annual outlook falls short of the higher analyst targets set between 6 November 2026 and 11 November 2026. Confirmed by: a 3 December 2026 fiscal 2027 revenue outlook no higher than $3,682–3,687 million, followed by analyst target cuts.
• Vault CRM go-lives at the largest drugmakers lag the selections, delaying the revenue the migration brings. Confirmed by: no increase from the five top-20 biopharma companies live on Vault CRM on 5 November 2026 at the 3 December 2026 report or the following one.
• Leadership turnover slows customer migrations after the President and Chief Customer Officer's departure announced on 2 November 2026. Confirmed by: further senior departures or a slower pace of Vault CRM go-lives reported at the 3 December 2026 report.
• A broad enterprise software sell-off pulls Veeva down regardless of its own results. Confirmed by: large enterprise software peers cutting outlooks in their December reports and the group's shares falling together.

What it trades with

Veeva trades with the enterprise software group, and a sector-wide software sell-off would weigh on it regardless of company results. Stock Observer listed its beta, a measure of sensitivity to the broad market, at 0.89 on 6 November 2026. Its revenue depends on biopharma research and commercial budgets, which ties it to drug-industry spending. Partners such as IQVIA, which said on 13 October 2026 that four Veeva clinical applications would become its standard, link part of its clinical growth to contract research organizations.